-+ 0.00%
-+ 0.00%
-+ 0.00%

Fulcrum Therapeutics Q4 EPS $(0.31), Inline

Benzinga·02/24/2026 12:42:41
Listen to the news
Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.31) per share which met the analyst consensus estimate. This is unchanged from the same period last year.